<DOC>
	<DOCNO>NCT03018223</DOCNO>
	<brief_summary>The purpose study find combination drug ( call : cyclophosphamide , sirolimus , mycophenolate mofetil ) protect participant well graft vs. host disease ( GVHD ) receive hematopoietic cell transplant relate partially match ( haploidentical ) donor . As part treatment blood cancer , participant need hematopoietic cell transplantation ( HCT ) improve chance cure . In HCT , stem cell infusion give , combination drug need prevent GVHD facilitate acceptance graft .</brief_summary>
	<brief_title>Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>Patient Participants : Age : Up 65 year full intensity ( myeloablative ) , age limit reduce intensity . Karnofsky performance status : Full intensity conditioning , 80100 % ; reduce intensity conditioning , 60100 % . Vital organ function : ) Cardiac : Left ventricular ejection fraction must &gt; 45 % assess multigated acquisition ( MUGA ) scan echocardiogram . No myocardial infarction within 6 month transplant evaluation . b ) Pulmonary : forced expiratory volume one second ( FEV1 ) , force vital capacity ( FVC ) , adjust diffuse capacity lung carbon monoxide ( DLCO ) must ≥ 50 % predicted value . c ) Liver : Transaminases ( AST , ALT ) less 2 time upper limit normal value . ) Kidney : Estimated creatinine clearance ≥ 50 cc/min . Signed informed consent . Included disease condition remission status : ) Acute leukemia First Complete Remission ( CR1 ) second/subsequent CR . b ) Chronic myeloid leukemia , primary myelofibrosis , chronic myelomonocytic leukemia . c ) Int2 high risk myelodysplastic syndrome ( MDS ) . ) Hodgkin lymphoma beyond CR1 chemosensitive disease , Stable Disease ( SD ) may include mass &gt; 3 cm . e ) NonHodgkin lymphoma high risk CR1 subsequent CR ( clinical , cytogenetic molecular criterion ) , primary induction failure ( PIF ) relapse chemosensitive disease . SD may include mass &gt; 3 cm . f ) Multiple myeloma CR/Very Good Partial Response ( VGPR ) . Donor Participants : Per Moffitt Cancer Center ( MCC ) Blood Marrow Transplant ( BMT ) program practice , allele level match ( 8/8 HLA A , B , C DR ) sibling unrelated donor prefer . If match donor find , mismatch unrelated haploidentical donor may consider . If haploidentical donor consider , parent , child full sibling high resolution type MCC HLA laboratory . Patient potential haploidentical donor select among share least one human leukocyte antigenA ( HLAA ) , B , C , DRB1 DQB1 haplotype . A donor may 5 , 6 7 10 HLA identical recipient . Patient screen antibody target mismatch HLA antigens potential haploidentical donor ( donor specific antibody , DSA ) . Antibody screen confirmatory test use Luminex single antigenbead test do . Among several potential donor , choose order priority : ) Matched cytomegalovirus ( CMV ) immunoglobulin G ( IgG ) serologic status donor recipient . b ) ABO blood group systemmatched donor prefer , minor ABO mismatch , major ABO mismatch . c ) Younger donor prefer : child , sibling , parent . ) For male recipient , male donor prefer . Avoid mother donor unless choice . Patient Participants : Active bacterial , viral , fungal infection control appropriate antimicrobial therapy . History HIV infection . HCT comorbidity index total score &gt; 3.28 Adjusted DLCO include assessment pulmonary risk , except DLCO le 50 % exclude . Prior allogeneic HCT . Unwilling comply study requirement . Active , progressive advance disease base diagnosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Acute leukemia CR</keyword>
	<keyword>Chronic myeloid leukemia</keyword>
	<keyword>Non-Hodgkin lymphoma high risk</keyword>
	<keyword>Graft v . Host Disease</keyword>
	<keyword>GVHD</keyword>
	<keyword>Hematopoietic cell transplant ( HCT )</keyword>
</DOC>